From Fatigued to Fantastic!
Page 48
131. M. T. Salam, Y. F. Yi, et al., “Maternal Fish Consumption During Pregnancy and Risk of Early Childhood Asthma,” J Asthma 2005; 42 (6): 513–518.
132. http://www.npicenter.com/anm/templates/newsATemp.aspx?articleid=14384& zoneid=41
133. M. Peet and C. Stokes, “Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders,” Drugs 2005; 65 (8): 1051–1059.
134. S. Frangou, M. Lewis, and P. McCrone, “Efficacy of Ethyl-Eicosapentaenoic Acid in Bipolar Depression: Randomized Double-Blind Placebo-Controlled Study,” Br J Psychiatry 2006; 188: 46–50.
135. A. Elvin, A. K. Siosteen, A. Nilsson, and E. Kosek, “Decreased Muscle Blood Flow in Fibromyalgia Patients During Standardised Muscle Exercise: A Contrast Media Enhanced Colour Doppler Study,” Eur J Pain 2006 February; 10 (2): 137–144.
Chapter 7. Natural and Prescription Pain Relief for Fibromyalgia
1. S. Chrubasik et al., “Treatment of Low Back Pain Exacerbations with Willow Bark Extract: A Randomized Double-Blind Study,” American Journal of Medicine 2000 July; 109 (1): 9–14.
2. S. Chrubasik, O. Kunzel, et al., “Potential Economic Impact of Using a Proprietary Willow Bark Extract in Outpatient Treatment of Low Back Pain: An Open Non-Randomized Study,” Phytomedicine 2001 July; 8 (4): 241–251.
3. R. W. Marz and F. Kemper, “Willow Bark Extract—Effects and Effectiveness: Status of Current Knowledge Regarding Pharmacology, Toxicology and Clinical Aspects” (Article in German), Wien Med Wochenschr, 2002; 152 (15–16): 354–359.
4. B. Schmid et al., “Efficacy and Tolerability of a Standardized Willow Bark Extract in Patients with Osteoarthritis: Randomized Placebo-Controlled, Double Blind Clinical Trial.” Phytother Res 2001 June; 15 (4): 344–350.
5. E. S. Highfield and K. J. Kemper, “White Willow Monograph,” Longwood Herbal Task Force. Accessed on June 7, 2004. Available at: http://www.mcp.edu/herbal/ willowbark/willow.pdf
6. T. Hedner and B. Everts, “The Early Clinical History of Salicylates in Rheumatology and Pain,” Clinical Rheumatology 1998; 17: 17–25.
7. S. Chrubasik and E. Eisenberg, “Treatment of Rheumatic Pain with Herbal Medicine in Europe,” Pain Digest 1998; 8: 231–236.
8. B. Meier, O. Sticher, and R. Julkunen-Tiitto, “Pharmaceutical Aspects of the Use of Willows in Herbal Remedies,” Planta Medica 1988: 559–560.
9. G. B. Singh et al., Agents and Actions 1986; 18: 407.
10. M. L. Sharma et al., Agents and Actions 1988; 24: 161.
11. M. L. Sharma et al., International Journal Immunopharm, 1989; 11: 647.
12. A. Kar and M. K. Menon, Life Sciences 1969; 8: 1023.
13. M. K. Menon and A. Kar, Planta Medica 1971; 19: 333.
14. O. Sander, G. Herborn, and R. Rau, “[Is H15 (Resin Extract of Boswellia serrata, “incense”) a Useful Supplement to Established Drug Therapy of Chronic Polyarthritis? Results of a Double-Blind Pilot Study],” Z Rheumatol 1998; 57: 11–16. German.
15. M. L. Sharma et al., Agents and Actions 1988; 24: 161.
16. R. Etzel, Phytomedicine 1996; 3 (1): 91–94.
17. N. Kimmatkar, V. Thawani, L. Hingorani, et al., Phytomedicine 2003; 10 (1): 3–7.
18. H. Safayhi et al., “Inhibition by Boswellic Acids of Human Leukocyte Elastase,” Journal of Pharmacological Experimental Therory 1997 April; 281 (1): 460–463.
19. I. Gupta et al., “Effects of a Boswellia Resin in Patients with Bronchial Asthma: Results of a Double-Blind, Placebo-Controlled, Six Week Clinical Study,” European Journal of Medical Research, 1998; 3: 511–514.
20. I. Gupta et al., “Effects of Gum Resin of Boswellia Serrata in Patients with Chronic Colitis,” Planta Medica 2001 July; 67 (5): 391–395.
21. K. Hostanska et al., “Cytostatic and Apoptosis-Inducing Activity of Boswellic Acids Toward Malignant Cell Lines in Vitro,” Anticancer Res, 2002 September-October; 22 (5): 2853–2862.
22. M. T. Huang et al., “Anti-tumor and Anti-carcinogenic Activities of Triterpenoid, Beta-Boswellic Acid,” Biofactors 2000; 13 (1–4): 225–230.
23. N. P. Seeram et al., “Cyclooxygenase Inhibitory and Antioxidant Cyanidin Glycosides in Cherries and Berries,” Phytomedicine 2001 September; 8 (5): 362–369.
24. S. Y. Kang et al., “Tart Cherry Anthocyanins Inhibit Tumor Development in Apc(Min) Mice and Reduce Proliferation of Human Colon Cancer Cells,” Cancer Letter 2003 May 8; 194 (1): 13–19.
25. L. W. Blau, “Cherry Diet Control for Gout and Arthritis,” Tex Report on Biol Medicine 1950; 8: 309–311.
26. K. C. Srivastava and T. Mustafa, “Ginger (Zingiber officinale) in Rheumatism and Musculoskeletal Disorders,” Medical Hypotheses 39 (4) (December 1992): 342–348.
27. V. Challapalli, I. W. Tremont-Lukats, E. D. McNicol, J. Lau, and D. B. Carr, “Systemic Administration of Local Anesthetic Agents to Relieve Neuropathic Pain,” Cochrane Database Syst Rev 19; (4): CD003345, 2005.
28. M. C. Rowbotham, L. A. Reisner-Keller, and H. L. Fields, “Both Intravenous Lidocaine and Morphine Reduce the Pain of Postherpetic Neuralgia,” Neurology 1991, 41: 1024–1028.
29. J. Sorenson, A. Bengtsson, E. Backman, K. G. Henriksson, and M. Bengtsson, “Pain Analysis in Patients with Fibromyalgia: Effects of Intravenous Morphine, Lidocaine and Ketamine,” Scan J Rheumatol 1995, 24: 360–365.
30. M. I. Bennett and Y. M. Tai, “Intravenous Lignocaine in the Management of Primary Fibromyalgia Syndrome,” Int J Clin Pharm Res 1995, 15: 115–119.
Chapter 8. More Natural Remedies
1. Juneja et al., Trends in Food Sci Tech 1999; 199–204. Kobayashi et al., Nippon Nogeikagaku Kaishi 1998; 72: 153–157.
2. Kakuda et al., 2000; 64: 287–293.
3. Y. N. Singh and M. Blumenthal, “Kava: An Overview,” Herbalgram 39 (Spring 1997): 33–55.
4. G. Piscopo, “Kava Kava: Gift of the Islands,” Alternative Medicine Review 2 (5) (1997): 355–364.
5. E. Grassel, “Effect of Ginkgo Biloba Extract on Mental Performance,” Fortschritte der Medizin 110 (5) (February 1992): 73–76.
6. W. Hopfenmuller, “Proof of the Therapeutic Effectiveness of a Ginkgo Biloba Extract—A Meta Analysis of 11 [Placebo-Controlled] Trials in Aged Patients with Cerebral Insufficiency,” Arzneimittel-Forschung 44 (9) (September 1994): 1005–1010.
7. I. Hindmarch, “Activity of Ginkgo Biloba Extract on Short Term Memory,” Presse Medicale 15 (31) (September 1986): 1592–1594.
7A.A. Tamborini and R. Taurelle, “Value of Standardized Ginkgo Biloba Extract (EGb 761) in the Management of Congestive Symptoms of Premenstrual Syndrome,” Revue Francaise de gynecologie et d’Obstetrique 88 (7–9) (July-September 1993): 447–457.
8. J. P. Haguenauer, F. Cantenot, H. Koskas, et al., “Treatment of Equilibrium Disturbances with Ginkgo Biloba—A Multicenter, Placebo Controlled Study,” Presse Medicale 15 (31) (25 September 1986): 1569–1572.
9. P. F. Smith and C. L. Darlington, “Can Vestibular Compensation Be Enhanced by Drug Treatment? A Review of Recent Evidence” review, Journal of Vestibular Research 4 (3) (May-June 1994): 169–179.
10. D. F. Neri, D. Wiegmann, R. R. Stanny, et al., “The Effects of Tyrosine on Cognitive Performance During Extended Wakefulness,” Aviation, Space, and Environmental Medicine 66 (4) (1995): 313–319.
11. R. H. Wolbling et al., “Local Therapy of Herpes Simplex with Dried Extract From Melisa Officianalis,” Phyto Medicine 1 (1994): 25–31.
12. P. J. Meunier et al., “Strontium Ranelate: Dose-Dependent Effects on Established Postmenopausal Vertebral Osteoporosis—a Two-Year Randomized Placebo-Controlled Trial,” Journal of Clinical Endocrinology and Metabolism, May 2002; 87 (5): 2060–2066.
13. P. J. Meunier et al., “The Effects of Strontium on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis,” New England Journal of Medicine, 2004, January 29; 350 (5): 459–468.
14. F. E. McCaslin et al., “The Effect of Strontium Lactate in the Treatment of Osteoporosis,” Proceedings of the Staff Meetings of the Mayo Clinic 34: 1959; 329–334.
> Chapter 9. Other Areas to Explore
1. S. B. Miller, “IgG Food Allergy Testing by ELISA/EIA—What Do They Really Tell Us?” Townsend Letter for Doctors and Patients, January 1998, pp. 62–66, 106.
2. R. M. Jaffe, “A Novel Treatment for Fibromyalgia Improves Clinical Outcomes in a Community Based Study,” study presented before the American Association for the Advancement of Science, Baltimore, MD, 9 February 1996.
3. R. Shoemaker and D. E. House, “Sick Building Syndrome (SBS) and Exposure to Water-Damaged Buildings,” Neurotoxicology and Teratology 28 (2006) 573–588. Available online at www.sciencedirect.com.
4. B. Hurwitz et al., “Therapeutic Effect of Epoetin Alpha on RBC Volume, Perceived Fatigue and Susceptibility to Syncope in CFS,” IACFS Conference abstract and presentation. Ft. Lauderdale, FL, January 12–14, 2007.
5. R. Shoemaker and M. S. Maizel, “Treatment of CFS patients with Elevated C4A Using Low Dose Erythropoietin Corrects Abnormalities in CNS Metabolites and Restores Executive Cognitive Functioning,” IACFS Conference abstract, Ft. Lauderdale, FL, January 12–14, 2007.
6. S. Ruhrmann and S. Kasper, “Seasonal Depression,” Medizinische Monatsschrift für Pharmazeuten 15 (1992): 293–299.
7. J. Liebermann and D. S. Bell, “Serum Angiotensin-Converting Enzyme as a Marker for the Chronic Fatigue-Immune Dysfunction Syndrome: A Comparison to Serum Angiotensin-Converting Enzyme in Sarcoidosis,” American Journal of Medicine 95 (1993): 407–412.
8. J. Goldstein, “Fibromyalgia Syndrome: A Pain Modulation Disorder Related to Altered Limbic Function?” Bailliere’s Clinical Rheumatology 8 (November 1994): 777–800.
9. S. Rogers, Tired or Toxic (Syracuse, NY: Prestige Publishing, 1990). S. Rogers, “Chemical Sensitivity: Breaking the Paralyzing Paradigm, Part I,” Internal Medicine World Report 7 (3): 1.
10. T. H. Park, “Comprehensive Treatments with IVIG for CFS,” IACFS Conference abstract, Ft. Lauderdale, FL, January 12–14, 2007.
Chapter 10. Am I Crazy? Understanding the Mind-Body Connection
1. E. K. Axe et al., “Major Depressive Disorder in Chronic Fatigue Syndrome: A CDC Surveillance Study,” Journal of Chronic Fatigue Syndrome, Vol. 12 (3) 2004.
2. I. Castro, F. Barrantes, M. Tuna, G. Cabrera, C. Garcia, M. Recinos, L. R. Espinoza, and A. Garcia-Kutzbach, “Prevalence of Abuse in Fibromyalgia and Other Rheumatic Disorders at a Specialized Clinic in Rheumatic Diseases in Guatemala City,” Clin Rheumatol 2005 June; 11 (3): 140–145.
3. http://www.medscape.com/viewarticle/544942 ECNP 19th Congress: Presentation S. 13.05. Presented September 18, 2006.
Appendix G: For Physicians
1. F. Wolfe, K. Ross, J. Anderson, et al., “The Prevalence and Characteristics of Fibromyalgia in the General Population,” Arthritis and Rheumatism 38 (1) (January 1995): 19–28.
2. J. E. Teitelbaum and B. Bird, “Effective Treatment of Severe Chronic Fatigue: A Report of a Series of 64 Patients,” Journal of Musculoskeletal Pain 3 (4) (1995): 91–110.
3. J. E. Teitelbaum, B. Bird, R. M. Greenfield, et al., “Effective Treatment of CFS and FMS: A Randomized, Double-Blind Placebo-Controlled Study,” Journal of Chronic Fatigue Syndrome 8 (2) (2001). The full text of the study can be found at www.vitality101.com.
4. M. A. Demitrack, K. Dale, S. E. Straus, et al., “Evidence for Impaired Activation of the Hypothalamic-Pituitary-Adrenal Axis in Patients with Chronic Fatigue Syndrome,” Journal of Clinical Endocrinology and Metabolism 73 (6) (December 1991): 1223–1234.
5. J. E. Teitelbaum, “Estrogen and Testosterone in CFIDS/FMS,” From Fatigued to Fantastic! newsletter, February 1997.
6. P. O. Behan, “Post-viral Fatigue Syndrome Research,” in The Clinical and Scientific Basis of Myalgic Encephalitis and Chronic Fatigue Syndrome, Byron Hyde, Jay Goldstein, and Paul Levine, eds. (Ottawa, Ontario, Canada: Nightingale Research Foundation, 1992), p. 238.
7. J. E. Teitelbaum, “Mitochondrial Dysfunction [in CFS/FMS],” From Fatigued to Fantastic! newsletter 1 (2) (1997). Contains numerous references on this topic.
8. F. Wolfe et al., “The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: Report of the Multicenter Criteria Committee,” Arthritis and Rheumatology 33 (1990): 160–172.
9. H. Blatman, editorial, Journal of the American Academy of Pain Management, April 2002.
10. Conference on the Neuroscience and Endocrinology of Fibromyalgia Syndrome, sponsored by the National Institutes of Health, 16–17 July 1996.
11. T. Fleming, ed., “Jamaican Dogwood” PDR for herbal medicines, 1998 pp. 428–429.
12. “Humulus Lupus,” Monograph. Alternative Medicine Review, 8 (2) 2003, 190–192.
13. J. R. Cronin, “Passionflower—Reigniting Male Libido and Other Potential Uses,” Alternative and Complementary Therapies April 2003, pp. 89–92.
14. K. Dhawan et al., “Reversal of Morphine Tolerance and Dependence by Passiflora Incarnata,” Pharmaceutical Biology 2002; 40 (8): 576–580.
15. S. Hadley et al. “Valerian,” American Family Physician 2003; 67 (8): 1755–1758.
16. M. B. Yunus and J. C. Aldag, “Restless Leg Syndrome and Leg Cramps in Fibromyalgia Syndrome: A Controlled Study,” British Medical Journal 312 (7042) (25 May 1996): 1339.
17. J. C. Lowe, R. L. Garrison, A. J. Reichman, J. Yellin, M. Thompson, and D. Kaufman, “Effectiveness and Safety of T3 Therapy for Euthyroid Fibromyalgia: A Double-Blind, Placebo-Controlled Response Driven Crossover Study,” Clinical Bulletin of Myofascial Therapy 1997: 2 (2/3): 31–58.
18. J. C. Lowe, A. J. Reichman, and J. Yellin, “The Process of Change During T3 Treatment for Euthyroid Fibromyalgia: A Double-Blind, Placebo-Controlled, Crossover Study,” Clinical Bulletin of Myofascial Therapy 1997; 2 (2/3): 91–124.
19. G. Faglia, L. Bitensky, A. Pinchera, et al., “Thyrotropin Secretion in Patients with Central Hypothyroidism: Evidence for Reduced Biological Activity of Immunoreactive Thyrotropin,” Journal of Clinical Endocrinology and Metabolism 48 (6) (June 1979) 989–998.
20. G. R. B. Skinner, D. Holmes, A. Ahmad, et al., “Clinical Response to Thyroxine Sodium in Clinically Hypothyroid but Biochemically Euthyroid Patients,” Journal of Nutritional and Environmental Medicine 10 (2) (June 2000): 115–125.
21. R. A. Nordyke, T. S. Reppun, L. D. Madanay, et al., “Alternative Sequences of Thyrotropin and Free Thyroxine Assays for Routine Thyroid Function Testing. Quality and Cost,” Archives of Internal Medicine 158 (3) (9 February 1998): 266–272.
22. E. N. Griep, J. N. Boersma, and E. R. de Kloet, “Altered Reactivity of the Hypothalamic-Pituitary Axis in the Primary Fibromyalgia Syndrome,” Journal of Rheumatology 20 (3) (March 1993): 469–474.
23. G. A. McCain and K. S. Tilbe, “Diurnal Hormone Variation in Fibromyalgia Syndrome and a Comparison with Rheumatoid Arthritis,” Journal of Rheumatology 25 (1993): 469–474.
24. W. M. Jefferies, Safe Uses of Cortisol, 2nd ed., monograph (Springfield, IL: Charles C. Thomas, 1996).
25. W. M. Jefferies, “Low-Dosage Glucocorticoid Therapy. An Appraisal of Its Safety and Mode of Action in Clinical Disorders, Including Rheumatoid Arthritis,” Archives of Internal Medicine 119 (3) (March 1967): 265–278.
26. R. McKenzie, A. O’Fallon, J. Dale, et al., “Low-Dose Hydrocortisone for Treatment of Chronic Fatigue Syndrome: A Randomized Controlled Trial,” Journal of the American Medical Association 280 (12) (23–30 September 1998): 1061–1066.
27. J. E. Teitelbaum, B. Bird, A. Weiss, et al., “Low Dose Hydrocortisone for Chronic Fatigue Syndrome,” Journal of the American Medical Association 281 (1999): 1887–1888.
28. A. J. Morales, J. J. Nolan, J. C. Nelson, et al., “Effects of Replacement Dose of Dehydroepiandrosterone in Men and Women of Advancing Age,” Journal of Clinical Endocrinology and Metabolism 78 (6) (June 1994): 1360–1367.
29. Elizabeth Lee Vliet, Screaming to Be Heard: Hormone Connections Women Suspect…and Doctors Ignore (New York, NY: M. Evans and Company, 1995).
30
. J. V. Wright and L. Lenard, Maximize Your Vitality and Potency, for Men Over 40, Smart Publications; 1999 (an excellent reference for those who would like to explore the topic further).
30A. L. S. Marks et al., “Effect of Testosterone Replacement Therapy on Prostate Tissue in Men with Late-Onset Hypogonadism: A Randomized Controlled Trial,” JAMA 2006; 296 (19): 2351–2361 (ISSN: 1538–3598).
30B. Arch Intern Med 2006; 166: 1660–1665.
31. R. S. Ivker, Sinus Survival (New York, NY: Tarcher/Putnam, 2000).
32. W. M. Becker, J. B. Reece, M. F. Poenie, et al., The World of the Cell, 3rd ed. (San Francisco, CA: Benjamin Cummings, 1996).
33. B. Regland, M. Andersson, L. Abrahamsson, et al., “Increased Concentrations of Homocysteine in the Cerebrospinal Fluid in Patients with Fibromyalgia and Chronic Fatigue Syndrome,” Scandinavian Journal of Rheumatology 26 (4) (1997), 301–307.
34. J. Lindenbaum, I. H. Rosenberg, P. W. Wilson, et al., “Prevalence of Cobalamin Deficiency in the Framingham Elderly Population,” American Journal of Clinical Nutrition 60 (1) July 1994; 2–11.
35. J. Lindenbaum, E. B. Healton, D. G. Savage, et al., “Neuropsychiatric Disorders Caused by Cobalamin Deficiency in the Absence of Anemia or Macrocytoses,” New England Journal of Medicine 318 (26) (30 June 1988): 1720–1728.
36. W. S. Beck, “Cobalamin and the Nervous System,” editorial, New England Journal of Medicine 318 (26), (30 June 1988): 1752–1754.
37. Ibid.; and S. Chrubasik, et al., “Treatment of Low Back Pain Exacerbations with Willow Bark Extract: A Randomized Double-Blind Study,” American Journal of Medicine, 2000 July; 109 (1): 9–14.
38. S. Chrubasik, O. Kunzel, et al., “Potential Economic Impact of Using a Proprietary Willow Bark Extract in Outpatient Treatment of Low Back Pain: An Open Non-randomized Study,” Phytomedicine, 2001 July; 8 (4): 241–251.
39. R. W. Marz and F. Kemper, “Willow Bark Extract—Effects and Effectiveness. Status of Current Knowledge Regarding Pharmacology, Toxicology and Clinical Aspects,” [Article in German] Wien Med Wochenschr 2002; 152 (15–16): 354–359.